Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

European Journal of Clinical Pharmacology

Volumn 63, Issue 4, 2007, Pages 321-333

  Frank, D ^a   Jaehde, U ^b   Fuhr, U ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

CYP2D6 phenotyping; Debrisoquine; Dextromethorphan; Metoprolol; Sparteine; Tramadol

Indexed keywords

2 DEHYDROSPARTEINE; 3 METHOXYMORPHINAN; 4 DEHYDRODEBRISOQUINE; 4 HYDROXYDEBRISOQUINE; 5 DEHYDROSPARTEINE; ALPHA HYDROXYMETOPROLOL; CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DEBRISOQUINE; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; METOPROLOL; NORLEVORPHANOL; O NORTRAMADOL; PAROXETINE; QUINIDINE; SPARTEINE; SPARTEINE SULFATE; TRAMADOL; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BLOOD ANALYSIS; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG OXIDATION; DRUG SALIVA LEVEL; DRUG URINE LEVEL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MEDLINE; METABOLIC RATE; MOLECULAR PROBE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SALIVA ANALYSIS; URINALYSIS; URINE PH; VALIDATION STUDY;

AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DEXTROMETHORPHAN; EVALUATION STUDIES; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 33947180388     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0250-8     Document Type: Review

References (88)

1. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R, Liao S, Spielberg SP, Kearns GL (2002) Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 42:24-29
2. al-Hadidi HF, Irshaid YM, Rawashdeh NM (1994) Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians. Eur J Clin Pharmacol 47:311-314
3. Barnhart JW (1980) The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol 55:43-48
4. Basci NE, Bozkurt A, Kayaalp SO, Sayal A, Isimer A (1998) Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan. Eur J Drug Metab Pharmacokinet 23:1-5
5. Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU (1980) Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol 17:153-155
6. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111-122
7. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258
8. Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209-218
9. Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC (2005) Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos 33:1052-1055
10. Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO (1996) Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study. Eur J Drug Metab Pharmacokinet 21:309-314
11. Brosen K, Otton SV, Gram LF (1986) Sparteine oxidation polymorphism: a family study. Br J Clin Pharmacol 21:661-667
12. Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA (1996) The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther 60:295-307
13. Cerqueira PM, Coelho EB, Geleilete TJ, Goldman GH, Lanchote VL (2005) Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. J Clin Pharmacol 45:1422-1433
14. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther 74:437-447
15. Chladek J, Zimova G, Martinkova J, Tuma I (1999) Intraindividual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects. Fundam Clin Pharmacol 13:508-515
16. Chladek J, Zimova G, Beranek M, Martinkova J (2000) In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur J Clin Pharmacol 56:651-657
17. Dalen P, Dahl M, Andersson K, Bertilsson L (2000) Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Br J Clin Pharmacol 49:180-184
18. Dayer P, Desmeules J, Leemann T, Striberni R (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 152:411-416
19. Dayer P, Leemann T, Striberni R (1989) Dextromethorphan Odemethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther 45:34-40
20. Distlerath LM, Guengerich FP (1984) Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Proc Natl Acad Sci USA 81:7348-7352
21. Duche JC, Querol-Ferrer V, Barre J, Mesangeau M, Tillement JP (1993) Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population. Int J Clin Pharmacol Ther Toxicol 31:392-398
22. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183-187
23. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 31:184-186
24. Eichelbaum M, Mineshita S, Ohnhaus E, Zekorn C (1986) The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22:49-53
25. Evans WE, Relling MV (1991) Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1:143-148
26. Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther (in press)
27. Funck-Brentano C, Boelle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM (2005) Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 61:821-829
28. Fux R, Morike K, Prohmer AM, Delabar U, Schwab M, Schaeffeler E, Lorenz G, Gleiter CH, Eichelbaum M, Kivisto KT (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78:378-387
29. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827-2831
30. Granvil CP, Krausz KW, Gelboin HV, Idle JR, Gonzalez FJ (2002) 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther 301:1025-1032
31. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26
32. Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173
33. Hou ZY, Pickle LW, Meyer PS, Woosley RL (1991) Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 49:410-419
34. Hou ZY, Chen CP, Yang WC, Lai MD, Buchert ET, Chung HM, Pickle LW, Woosley RL (1996) Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis. Clin Pharmacol Ther 59:411-417
35. Hu OY, Tang HS, Lane HY, Chang WH, Hu TM (1998) Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 285:955-960
36. Jacqz E, Dulac H, Mathieu H (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35:167-171
37. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T (1993) CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204
38. Johnson JA, Burlew BS (1996) Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 24:350-355
39. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, Gaedigk A, Bertino JS Jr (1998) Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 8:403-410
40. Kevorkian JP, Michel C, Hofmann U, Jacqz-Aigrain E, Kroemer HK, Peraldi MN, Eichelbaum M, Jaillon P, Funck-Brentano C (1996) Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Clin Pharmacol Ther 59:583-592
41. Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44:1083-1105
42. Kim M, Shen DD, Eddy AC, Nelson WL, Roskos LK (1993) Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. Drug Metab Dispos 21:309-317
43. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473
44. Kivisto KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S-48S
45. Kohler D, Hartter S, Fuchs K, Sieghart W, Hiemke C (1997) CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 7:453-461
46. Kupfer A, Schmid B, Pfaff G (1986) Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 16:421-433
47. Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J, Hamelin BA (2000) Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425-438
48. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K (2005) Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77:312-323
49. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker LE, Woods HF (1982) Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med 307:1558-1560
50. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF (1983) Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 34:732-737
51. Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF (1992) Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2:89-92
52. Lu AY, Wang RW, Lin JH (2003) Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31:345-350
53. Lutz U, Volkel W, Lutz RW, Lutz WK (2004) LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation. J Chromatogr B Analyt Technol Biomed Life Sci 813:217-225
54. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586
55. Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O, Ingelman-Sundberg M (1996) Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 51:117-122
56. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 247:242-427
57. Ozdemir M, Crewe KH, Tucker GT, Rostami-Hodjegan A (2004) Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J Clin Pharmacol 44:1398-1404
58. Paar WD, Frankus P, Dengler J (1992) The metabolism of tramadol by human liver microsomes. Clin Investig 70:708-710
59. Paar WD, Poche S, Gerloff J, Dengler HJ (1997) Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesis tramadol. Eur J Pharmacol 53:235-239
60. Paar WD, Schuhler H, Fimmers R, Dengler HJ (1989) Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma. Eur J Clin Pharmacol 36:555-560 cytochrome P450 2D6. J Biol Chem 278:4021-4027
61. Pedersen RS, Damkier P, Brosen K (2005) Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 77:458-467
62. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH (1996) The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60:636-644
63. Rostami-Hodjegan A, Kroemer HK, Tucker GT (1999) In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 9:277-286
64. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
65. Schellens JH, Soons PA, van der Wart JH, Hoevers JW, Breimer DD (1991) Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man. Br J Clin Pharmacol 31:175-178
66. Schellens JH, van der Wart JH, Brugman M, Breimer DD (1989) Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 249:638-645
67. Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624
68. Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL (1983) Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 15:443-450
69. Sohn DR, Kusaka M, Shin SG, Jang IJ, Chiba K, Ishizaki T (1992) Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations. Ther Drug Monit 14:184-189
70. Sommers DK, Moncrieff J, Avenant J (1989) Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 8:365-368
71. Steiner E, Iselius L, Alvan G, Lindsten J, Sjoqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38:394-401
72. Streetman DS, Ellis RE, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr (1999) Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther 66:535-541
73. Streetman DS, Bertino JS Jr, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216
74. Subrahmanyam V, Renwick AB, Walters DG, Young PJ, Price RJ, Tonelli AP, Lake BG (2001) Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 29:1146-1155
75. Syvalahti EK, Lindberg R, Kallio J, De Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22:89-92
76. Takashima T, Murase S, Iwasaki K, Shimada K (2005) Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers. Drug Metab Pharmacokinet 20:177-182
77. Tamminga WJ, Wemer J, Oosterhuis B, Brakenhoff JP, Gerrits MG, de Zeeuw RA, de Leij LF, Jonkman JH (2001) An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. Eur J Clin Pharmacol 57:143-146
78. Tanaka E, Kurata N, Yasuhara H (2003) How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 28:157-165
79. Tegeder I, Lotsch J, Geisslinger G (1999) Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 37:17-40
80. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI (1998) Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 50:997-1004
81. Yeh GC, Tao PL, Ho HO, Lee YJ, Chen YJ, Sheu MT (2003) Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J Biomed Sci 10:552-564
82. Yu A, Dong H, Lang D, Haining RL (2001) Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos 29:1362-1365
83. Yu A, Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520
84. Yu AM, Idle JR, Herraiz T, Kupfer A, Gonzalez FJ (2003) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307-319
85. Zaigler M, Tantcheva-Poor I, Fuhr U (2000) Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther 38:1-9
86. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch Pharmacol 369:23-37
87. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH (2001) Assessment of cytochrome P450 activity by a fivedrug cocktail approach. Clin Pharmacol Ther 70:455-461
88. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76:536-544